What have novel imaging techniques revealed about metabolism in the aging brain?

Future Neurology

Volumn 9, Issue 3, 2014, Pages 341-354

  Lin, Ai Ling ^a   Rothman, Douglas L ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

aging; Alzheimer's disease; APOE4; A plaques; glucose metabolism; magnetic resonance spectroscopy; mild cognitive impairment; mitochondrial function; PET

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CHOLINE; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INOSITOL; N ACETYLASPARTIC ACID;

AGING; ALZHEIMER DISEASE; APOE4 GENE; BRAIN BLOOD FLOW; BRAIN METABOLISM; CARBON NUCLEAR MAGNETIC RESONANCE; DEGENERATIVE DISEASE; DRUG EFFICACY; EARLY DIAGNOSIS; ENERGY METABOLISM; ENERGY TRANSFER; GENETIC RISK; GLUCOSE METABOLISM; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MILD COGNITIVE IMPAIRMENT; MITOCHONDRIAL ENERGY TRANSFER; NEUROCHEMISTRY; NEUROENERGETICS; NEUROIMAGING; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION STATE; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION;

EID: 84901910946     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.14.13     Document Type: Review

References (112)

1. Sokoloff L, Reivich M, Kennedy C et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28, 897-916 (1977). (Pubitemid 8098854)
2. Cunnane S, Nugent S, Roy M et al. Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition 27, 3-20 (2011).
3. Hoyer S. Abnormalities of glucose metabolism in Alzheimer's disease. Ann. NY Acad. Sci. 640, 53-58 (1991).
4. Nagata K, Buchan RJ, Yokoyama E et al. Misery perfusion with preserved vascular reactivity in Alzheimer's disease. Ann. NY Acad. Sci. 826, 272-281 (1997). (Pubitemid 27478049)
5. Reiman EM, Caselli RJ, Chen K et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl Acad. Sci. USA 98, 3334-3339 (2001). (Pubitemid 32220846)
6. Bookheimer SY, Strojwas MH, Cohen MS et al. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 343, 450-456 (2000). (Pubitemid 30646483)
7. Sokoloff L. Measurement of local cerebral glucose utilization and its relation to local functional activity in the brain. Adv. Exp. Med. Biol. 291, 21-42 (1991).
8. Phelps ME. PET Molecular Imaging and its Biological Applications. Springer, Berlin, Germany (2004).
9. Phelps ME, Huang SC, Hoffman EJ et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann. Neurol. 6, 371-388 (1979). (Pubitemid 10203423)
10. Mathis CA, Bacskai BJ, Kajdasz ST et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 12, 295-298 (2002). (Pubitemid 34113887)
11. Ono M, Wilson A, Nobrega J P et al. 11C-labeled stilbene derivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl. Med. Biol. 30, 565-571 (2003). (Pubitemid 37289318)
12. Agdeppa ED, Kepe V, Liu J et al. Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J. Neurosci. 21, RC189 (2001).
13. Boxer AL, Rabinovici GD, Kepe V et al. Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease. Neurology 69, 283-290 (2007). (Pubitemid 47205691)
14. Hyder F, Chase JR, Behar KL, Mason GF, Siddeek M et al. Increased tricarboxylic acid cycle flux in rat brain during forepaw stimulation detected with 1H[13C]NMR. Proc. Natl Acad. Sci. USA 93, 7612-7617 (1996).
15. Rothman DL, Behar KL, Hetherington HP et al. 1H-Observe/13C-decouple spectroscopic measurements of lactate and glutamate in the rat brain in vivo. Proc. Natl Acad. Sci. USA 82, 1633-1637 (1985). (Pubitemid 15079447)
16. Gruetter R, Seaquist ER, Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am. J. Physiol. Endocrinol. Metab. 281, e100-e112 (2001).
17. Mason GF, Petersen KF, de Graaf RA, Shulman GI, Rothman DL. Measurements of the anaplerotic rate in the human cerebral cortex using 13C magnetic resonance spectroscopy and [1-13C] and [2-13C] glucose. J. Neurochem. 100, 73-86 (2007). (Pubitemid 46085840)
18. Rothman DL, De Feyter HM, de Graaf RA, Mason GF, Behar KL. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 24, 943-957 (2011).
19. Rothstein JD, Dykes-Hoberg M, Pardo CA et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686 (1996). (Pubitemid 26103145)
20. Bergles DE, Diamond JS, Jahr CE. Clearance of glutamate inside the synapse and beyond. Curr. Opin. Neurobiol. 9, 293-298 (1999). (Pubitemid 29267599)
21. Hertz L, Peng L, Dienel GA. Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/ glycogenolysis. J. Cereb. Blood Flow Metab. 27, 219-249 (2007). (Pubitemid 46148451)
22. Sibson NR, Mason GF, Shen J et al. In vivo (13) C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during. J. Neurochem. 76, 975-989 (2001). (Pubitemid 32167371)
23. Yu AC, Drejer J, Hertz L, Schousboe A. Pyruvate carboxylase activity in primary cultures of astrocytes and neurons. J. Neurochem. 41, 1484-1487 (1983). (Pubitemid 14227465)
24. Zhu XH, Du F, Zhang N et al. Advanced in vivo heteronuclear MRS approaches for studying brain bioenergetics driven by mitochondria. Methods Mol. Biol. 489, 317-357 (2009).
25. Du F, Zhu XH, Qiao H, Zhang X, Chen W. Efficient in vivo31P magnetization transfer approach for noninvasively determining multiple kinetic parameters and metabolic fluxes of ATP metabolism in the human brain. Magn. Reson. Med. 57, 103-114 (2007). (Pubitemid 46067941)
26. Lu M, Zhu XH, Zhang Y, Chen W. Intracellular redox state revealed by in vivo P MRS measurement of NAD and NADH contents in brains. Magn. Reson. Med. doi:10.1002/mrm.24859 (2013) (Epub ahead of print).
27. Zhu XH, Lu M, Lee B-Y, Ugurbil K, Chen W. In vivo MR study of intracellular NAD contents and redox state in healthy human brain. Proc. Intl. Soc. Mag. Reson. Med. 22, 859 (2013).
28. Lee HC. Multiplicity of Ca2+ messengers and Ca2+ stores: a perspective from cyclic ADP-ribose and NAADP. Curr. Mol. Med. 4, 227-237 (2004). (Pubitemid 38515234)
29. Ying W. NAD+ and NADH in brain functions, brain diseases and brain aging. Front Biosci. 12, 1863-1888 (2007). (Pubitemid 46846813)
30. Ying W. NAD+ and NADH in cellular functions and cell death. Front Biosci. 11, 3129-3148 (2006). (Pubitemid 43800402)
31. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem. Sci. 32, 12-19 (2007).
32. Pollak N, Dolle C, Ziegler M. The power to reduce: pyridine nucleotides-small molecules with a multitude of functions. Biochem. J. 402, 205-218 (2007). (Pubitemid 46383418)
33. Chen S, Whetstine JR, Ghosh S et al. The conserved NAD(H)-dependent corepressor CTBP-1 regulates Caenorhabditis elegans life span. Proc. Natl Acad. Sci. USA 106, 1496-1501 (2009).
34. Eto K, Tsubamoto Y, Terauchi Y et al. Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion. Science 283, 981-985 (1999).
35. Garriga-Canut M, Schoenike B, Qazi R et al. 2-deoxy-d-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat. Neurosci. 9, 1382-1387 (2006). (Pubitemid 44646210)
36. Zhang Q, Wang SY, Nottke AC et al. Redox sensor CtBP mediates hypoxia-induced tumor cell migration. Proc. Natl Acad. Sci. USA 103, 9029-9033 (2006). (Pubitemid 43902527)
37. Baker EH, Basso G, Barker PB et al. Regional apparent metabolite concentrations in young adult brain measured by (1)H MR spectroscopy at 3 Tesla. J. Magn. Reson. Imaging 27, 489-499 (2008). (Pubitemid 351354732)
38. Adriany G, Gruetter R. A half-volume coil for efficient proton decoupling in humans at 4 tesla. J. Magn. Reson. 125, 178-184 (1997). (Pubitemid 127451368)
39. Klomp DW, Renema WK, van der Graaf M et al. Sensitivity-enhanced 13C MR spectroscopy of the human brain at 3 Tesla. Magn. Reson. Med. 55, 271-278 (2006). (Pubitemid 43238094)
40. Mason GF, Gruetter R, Rothman DL et al. Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J. Cereb. Blood Flow Metab. 15, 12-25 (1995).
41. Mason GF, Rothman DL. Basic principles of metabolic modeling of NMR (13)C isotopic turnover to determine rates of brain metabolism in vivo. Metab. Eng. 6, 75-84 (2004). (Pubitemid 38157797)
42. Moreno A, Bluml S, Hwang JH, Ross BD. Alternative 1-(13)C glucose infusion protocols for clinical (13)C MRS examinations of the brain. Magn. Reson. Med. 46, 39-48 (2001). (Pubitemid 32592137)
43. Mason GF, Falk Petersen K, de Graaf RA et al. A comparison of (13)C NMR measurements of the rates of glutamine synthesis and the tricarboxylic acid cycle during oral and intravenous administration of [1-(13)C]glucose. Brain Res. Brain Res. Protoc. 10, 181-190 (2003). (Pubitemid 36143919)
44. Herholz K, Salmon E, Perani D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17, 302-316 (2002).
45. Hsieh TC, Lin WY, Ding HJ et al. Sex-and age-related differences in brain FDG metabolism of healthy adults: an SPM analysis. J. Neuroimaging 22, 21-27 (2012).
46. Kalpouzos G, Chetelat G, Baron JC et al. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol. Aging 30, 112-124 (2009).
47. Zuendorf G, Kerrouche N, Herholz K, Baron JC. Efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Hum. Brain Mapp. 18, 13-21 (2003). (Pubitemid 35462612)
48. Petit-Taboue MC, Landeau B, Desson JF, Desgranges B, Baron JC. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage 7, 176-184 (1998). (Pubitemid 28372788)
49. Ibáñez V, Pietrini P, Furey ML et al. Resting state brain glucose metabolism is not reduced in normotensive healthy men during aging, after correction for brain atrophy. Brain Res. Bull. 63(2), 147-154 (2006). (Pubitemid 38591397)
50. Kochunov P, Ramage AE, Lancaster JL et al. Loss of cerebral white matter structural integrity tracks the gray matter metabolic decline in normal aging. Neuroimage 45, 17-28 (2009).
51. Peters R. Ageing and the brain. Postgrad. Med. J. 82, 84-88 (2006). (Pubitemid 43266135)
52. Dawson GR, Seabrook GR, Zheng H et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90, 1-13 (1999). (Pubitemid 29096448)
53. Devanand DP, Pradhaban G, Liu X et al. Hippocampal and entorhinal atrophy in mild cognitive impairment Prediction of Alzheimer disease. Neurology 68(11), 828-836 (2007). (Pubitemid 46568534)
54. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl Med. Mol. Imaging 32(4), 486-510 (2005). (Pubitemid 40591181)
55. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795 (2006). (Pubitemid 44622683)
56. Boumezbeur F, Mason GF, de Graaf RA et al. Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy. J. Cereb. Blood Flow Metab. 30, 211-221 (2010).
57. Lynch AM, Murphy KJ, Deighan BF et al. The impact of glial activation in the aging brain. Aging Dis. 1, 262-278 (2010).
58. Artero S, Tierney MC, Touchon J, Ritchie K. Prediction of transition from cognitive impairment to senile dementia: a prospective, longitudinal study. Acta Psychiatr. Scand. 107, 390-393 (2003). (Pubitemid 36606157)
59. Didic M, Ranjeva JP, Barbeau EJ et al. Magnetic resonance spectroscopic imaging detects metabolic changes within the medial temporal lobe in MCI. In: Handbook of Imaging the Alzheimer Brain. IOS Press, Amsterdam, The Netherlands, 561-570 (2011).
60. Cohen AD, Price JC, Weissfeld LA et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J. Neurosci. 29, 14770-14778 (2009).
61. Gilles C Age-related mild cognitive deficit: a ready-to-use concept? Dialogues Clin. Neurosci. 5, 61-76 (2003).
62. Landau SM, Harvey D, Madison CM et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238 (2010).
63. Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv. Drug Deliv. Rev. 60, 1504-1511 (2008).
64. Swerdlow RH. Brain aging, Alzheimer's disease, and mitochondria. Biochim. Biophys. Acta 1812(12), 1630-1639 (2011).
65. Swerdlow RH, Khan SM. A 'mitochondrial cascade hypothesis' for sporadic Alzheimer's disease. Med. Hypotheses 63, 8-20 (2004). (Pubitemid 38887104)
66. Mosconi L, de Leon M, Murray J et al. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. J. Alzheimers Dis. 27, 483-490 (2011).
67. Blass JP, Sheu RK, Gibson GE. Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise. Ann. NY Acad. Sci. 903, 204-221 (2000). (Pubitemid 30251560)
68. Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH. Coenzyme A-acetylating enzymes in Alzheimer's disease: possible cholinergic 'compartment' of pyruvate dehydrogenase. Neurosci. Lett. 18, 105-110 (1980). (Pubitemid 10122792)
69. Gibson GE, Sheu KF, Blass JP. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural. Transm. 105, 855-870 (1998). (Pubitemid 28539834)
70. Hauptmann S, Scherping I, Drose S et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol. Aging 30, 1574-1586 (2009).
71. Yao J, Irwin RW, Zhao L et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 14670-14675 (2009).
72. Galindo MF, Ikuta I, Zhu X, Casadesus G, Jordan J. Mitochondrial biology in Alzheimer's disease pathogenesis. J. Neurochem. 114, 933-945 (2010).
73. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 32, 486-510 (2005). (Pubitemid 40591181)
74. Mosconi L, Mistur R, Switalski R et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811-822 (2009).
75. Mosconi L, Tsui WH, Herholz K et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J. Nucl. Med. 49, 390-398 (2008). (Pubitemid 351355204)
76. Silverman DH, Small GW, Chang CY et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286, 2120-2127 (2001). (Pubitemid 34041597)
77. Minoshima S, Giordani B, Berent S et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 42, 85-94 (1997). (Pubitemid 27304784)
78. Blass JP. Alzheimer's disease and Alzheimer's dementia: distinct but overlapping entities. Neurobiol. Aging 23, 1077-1084 (2002). (Pubitemid 35447790)
79. Jones RS, Waldman AD. 1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia. Neurol. Res. 26, 488-495 (2004). (Pubitemid 38879230)
80. Lin AP, Shic F, Enriquez C, Ross BD. Reduced glutamate neurotransmission in patients with Alzheimer's disease-an in vivo (13)C magnetic resonance spectroscopy study. MAGMA 16, 29-42 (2003). (Pubitemid 38325346)
81. Mandal PK, Akolkar H, Tripathi M. Mapping of hippocampal pH and neurochemicals from in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive impairment, and Alzheimer's disease. J. Alzheimers Dis. 31(Suppl. 3), S75-S86 (2012).
82. Avidievich NI, Pan JW, Baehring JM, Spencer DD, Hetherington HP. Short echo spectroscopic imaging of the human brain at 7T using transceiver arrays. Magn. Reson. Med. 62(1), 17-25 (2009).
83. Haga KK, Khor YP, Farrall A, Wardlaw JM. Asystematic review of brain metabolite changes, measured with 1H magnetic resonance spectroscopy, in healthy aging. Neurobiol. Aging 30(3), 353-363 (2009).
84. Ross AJ, Sachdev PS, Wen W, Brodaty H. Longitudinal changes during aging using proton magnetic resonance spectroscopy. J. Gerontol A. Biol. Sci. Med. Sci. 61(3), 291-298 (2006).
85. Zahr NM, Mayer D, Pfefferbaum A, Sullivan EV. Low striatal glutamate levels underlie cognitive decline in the elderly: evidence from in vivo molecular spectroscopy. Cerebral Cortex 18(10), 2241-2250 (2008).
86. Kantarci K, Reynolds G, Petersen RC et al. Proton MR spectroscopy in mild cognitive impairment and Alzheimeris disease: comparison of 1.5T and 3T. AJNR Am. J. Neuroradiol. 24, 843-849 (2003). (Pubitemid 36617413)
87. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 55, 306-319 (2004). (Pubitemid 38269583)
88. Rowe CC, Ng S, Ackermann U et al. Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725 (2007). (Pubitemid 46763260)
89. Kemppainen NM, Aalto S, Wilson IA et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology 67, 1575-1580 (2006). (Pubitemid 44747926)
90. Mintun MA, Larossa GN, Sheline YI et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446-452 (2006). (Pubitemid 44214969)
91. Pike KE, Savage G, Villemagne VL et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844 (2007). (Pubitemid 350033975)
92. Jagust WJ, Landau SM, Shaw LM et al. Relationships between biomarkers in aging and dementia. Neurology 73, 1193-1199 (2009).
93. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (1984). (Pubitemid 14076461)
94. Kadir A, Almkvist O, Forsberg A et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol. Aging 33(198), e191-e114 (2012).
95. Engler H, Forsberg A, Almkvist O et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856-2866 (2006). (Pubitemid 44684508)
96. Edison P, Archer HA, Hinz R et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 68, 501-508 (2007).
97. Ingelsson M, Fukumoto H, Newell KL et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925-931 (2004). (Pubitemid 38435780)
98. Jack CR Jr, Lowe VJ, Weigand SD et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365 (2009).
99. Jack CR Jr, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128 (2010).
100. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24, 521-529 (1999).
101. Henderson ST, Vogel JL, Barr LJ et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond.) 6, 31 (2009).
102. Reger MA, Henderson ST, Hale C et al. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol. Aging 25, 311-314 (2004). (Pubitemid 38220966)
103. Jiang L, Mason GF, Rothman DL, de Graaf RA, Behar KL. Cortical substrate oxidation during hyperketonemia in the fasted anesthetized rat in vivo. J. Cereb. Blood Flow Metab. 31, 2313-2323 (2011).
104. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 9, 106-118 (2013).
105. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993). (Pubitemid 23275809)
106. Reiman EM, Chen K, Alexander GE et al. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl Acad. Sci. USA 101, 284-289 (2004). (Pubitemid 38084242)
107. Reiman EM, Chen K, Liu X et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106, 6820-6825 (2009).
108. Mosconi L, Rinne JO, Tsui WH et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc. Natl Acad. Sci. USA 107, 5949-5954 (2010).
109. Lin AL, Zheng W, Halloran JJ et al. Chronic rapamycin restores brain vascular integrity and function through NO synthase activation and improves memory in symptomatic mice modeling Alzheimer's disease. J. Cereb. Blood Flow Metab. 33, 1412-1421 (2013).
110. Sancheti H, Akopian G, Yin F et al. Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. PLoS ONE 8, e69830 (2013).
111. Lin A-L, Coman D, Jiang L, Rothman DL, Hyder F. Caloric restriction enhances oxidative brain metabolism in healthy aging detected by 1H[13C]MRS. Proc. Intl. Soc. Mag. Reson. Med. 118 (2013).
112. Lin AL, Laird AR, Fox PT, Gao JH. Multimodal MRI neuroimaging biomarkers for cognitive normal adults, amnestic mild cognitive impairment, and Alzheimer's disease. Neurol. Res. 2012, 907409 (2012).